Risk factors for cholangiocarcinoma
- PMID: 21488076
- PMCID: PMC3125451
- DOI: 10.1002/hep.24351
Risk factors for cholangiocarcinoma
Abstract
Cholangiocarcinoma (CC) is the second most common primary hepatic malignancy after hepatocellular cancer. CC accounts for approximately 10%-25% of all hepatobiliary malignancies. There are considerable geographic and demographic variations in the incidence of CC. There are several established risk factors for CC, including parasitic infections, primary sclerosing cholangitis, biliary-duct cysts, hepatolithiasis, and toxins. Other less-established potential risk factors include inflammatory bowel disease, hepatitis C virus, hepatitis B virus, cirrhosis, diabetes, obesity, alcohol drinking, tobacco smoking, and host genetic polymorphisms. In studies where the distinction between intra- and extrahepatic CC was used, some potential risk factors seem to have a differential effect on CC, depending on the site. Therefore, the consistent use of a more refined classification would allow a better understanding of risk factors for CC.
Copyright © 2011 American Association for the Study of Liver Diseases.
Similar articles
-
Risk factors for cholangiocarcinoma.Eur J Gastroenterol Hepatol. 2007 Aug;19(8):615-7. doi: 10.1097/MEG.0b013e328224b935. Eur J Gastroenterol Hepatol. 2007. PMID: 17625428 Review.
-
Epidemiology of cholangiocarcinoma.Best Pract Res Clin Gastroenterol. 2015 Apr;29(2):221-32. doi: 10.1016/j.bpg.2015.02.003. Epub 2015 Feb 16. Best Pract Res Clin Gastroenterol. 2015. PMID: 25966423 Review.
-
Primary sclerosing cholangitis and cholangiocarcinoma: pathogenesis and modes of diagnostics.Dig Dis. 2013;31(1):118-25. doi: 10.1159/000347206. Epub 2013 Jun 17. Dig Dis. 2013. PMID: 23797133 Review.
-
The epidemiology of cholangiocarcinoma.Semin Liver Dis. 2004 May;24(2):115-25. doi: 10.1055/s-2004-828889. Semin Liver Dis. 2004. PMID: 15192785 Review.
-
Clinical presentation, risk factors and staging systems of cholangiocarcinoma.Best Pract Res Clin Gastroenterol. 2015 Apr;29(2):245-52. doi: 10.1016/j.bpg.2015.02.001. Epub 2015 Feb 14. Best Pract Res Clin Gastroenterol. 2015. PMID: 25966425 Review.
Cited by
-
The pros and cons of the PCC staging system to guide surgical resectability and prognosis.J Cancer. 2022 Oct 9;13(13):3444-3451. doi: 10.7150/jca.76696. eCollection 2022. J Cancer. 2022. PMID: 36313036 Free PMC article. Review.
-
Biliary tree stem/progenitor cells in glands of extrahepatic and intraheptic bile ducts: an anatomical in situ study yielding evidence of maturational lineages.J Anat. 2012 Feb;220(2):186-99. doi: 10.1111/j.1469-7580.2011.01462.x. Epub 2011 Dec 5. J Anat. 2012. PMID: 22136171 Free PMC article.
-
High serum CA19-9 levels are associated with an increased risk of cholangiocarcinoma in patients with intrahepatic duct stones: a case-control study.Surg Endosc. 2013 Nov;27(11):4210-6. doi: 10.1007/s00464-013-3025-1. Epub 2013 Jun 13. Surg Endosc. 2013. PMID: 23760942
-
Obesity and cholangiocarcinoma.World J Gastroenterol. 2013 Jan 28;19(4):457-62. doi: 10.3748/wjg.v19.i4.457. World J Gastroenterol. 2013. PMID: 23382624 Free PMC article. Review.
-
Agrin expression is correlated with tumor development and poor prognosis in cholangiocarcinoma.J Int Med Res. 2021 May;49(5):3000605211009722. doi: 10.1177/03000605211009722. J Int Med Res. 2021. PMID: 34018826 Free PMC article.
References
-
- Gatto M, Bragazzi MC, Semeraro R, Napoli C, Gentile R, Torrice A, et al. Cholangiocarcinoma: update and future perspectives. Dig Liver Dis. 2010 Apr;42(4):253–260. - PubMed
-
- Patel T. Cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol. 2006 Jan;3(1):33–42. - PubMed
-
- Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis. 2004 May;24(2):115–125. - PubMed
-
- Blechacz BR, Gores GJ. Cholangiocarcinoma. Clin Liver Dis. 2008 Feb;12(1):131–50. ix. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical